Clinical monitoring and correlates of nephropathy in SIV-infected macaques during high-dose antiretroviral therapy.
BACKGROUND
In many preclinical AIDS research studies, antiretroviral therapy (ART) is administered to experimentally simian immunodeficiency (SIV)-infected rhesus macaques for reduction of viral load to undetectable levels. Prolonged treatment of macaques with a high dose of PMPA (9-[2-(r)-(phosphonomethoxy) propyl] adenine or tenofovir; 30 mg/kg of body weight subcutaneously once daily) can result in proximal renal tubular dysfunction, a Fanconi-like syndrome characterized by glucosuria, aminoaciduria, hypophosphatemia, and bone pathology. In contrast, chronic administration of a low dose of PMPA (10 mg/kg subcutaneously once daily) starting at birth does not seem to be associated with any adverse health effects within 3 years of treatment. In contrast to PMPA, limited information on systemic toxicity in rhesus monkeys is available for FTC (5-fluoro-1-(2R,5S)-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine; emtricitabine) and stavudine (d4T).


RESULTS
In this study, the clinical and biochemical correlates of tubular nephrosis in SIV-infected rhesus macaques associated with systemic administration of high-dose ART consisting of the three nucleoside analog inhibitors PMPA, FTC, and d4T were investigated. It was found that acute renal failure was uncommon (7.1% of treated animals) and that morphologic evidence of nephropathy, which persisted for more than 300 days following discontinuation of the drug cocktail, was more frequent (52.4% of treated animals). While parameters from single time points lacked predictive value, biochemical alterations in Blood Urea Nitrogen (BUN) and phosphorus were frequently identified longitudinally in the blood of ART-treated animals that developed evidence of nephropathy, and these longitudinal changes correlated with disease severity.


CONCLUSIONS
Recommendations are proposed to limit the impact of drug-induced renal disease in future SIV macaque studies.
Southern Research Institute, Frederick, MD, USA. bsanders@bioqual.com.
Brigitte E
BE
Sanders-Beer
Yvette Y
YY
Spano
Dawn
D
Golighty
Abigail
A
Lara
Diane
D
Hebblewaite
Lourdes
L
Nieves-Duran
Lowrey
L
Rhodes
Keith G
KG
Mansfield
Am J Kidney Dis. 2000 Nov;36(5):1075-8
11054370
Antimicrob Agents Chemother. 1998 Mar;42(3):687-90
9517952
Mol Pharm. 2009 Jul-Aug;6(4):1145-51
19545170
AIDS Res Hum Retroviruses. 1997 May 20;13(8):707-12
9168239
Antimicrob Agents Chemother. 2004 May;48(5):1469-87
15105094
AIDS Res Hum Retroviruses. 1998 Jun 10;14(9):761-73
9643376
AIDS. 2005 May 20;19(8):844-5
15867505
AIDS Res Hum Retroviruses. 1998 Sep 1;14(13):1163-80
9737588
AIDS Res Hum Retroviruses. 1997 Mar 20;13(5):413-24
9075483
AIDS Res Hum Retroviruses. 2008 Aug;24(8):1103-16
18620495
PLoS Med. 2008 Feb;5(2):e28
18254653
Science. 1995 Nov 17;270(5239):1197-9
7502044
J Acquir Immune Defic Syndr Hum Retrovirol. 1999 Apr 1;20(4):323-33
10096575
J Virol. 2000 Feb;74(4):1767-74
10644348
Adv Chronic Kidney Dis. 2006 Jul;13(3):314-9
16815236
FASEB J. 2008 Mar;22(3):659-61
17942826
J Virol. 1998 Nov;72(11):8820-32
9765427
Antimicrob Agents Chemother. 2008 Sep;52(9):3144-60
18573931
AIDS. 1993 Jan;7(1):131-2
8442906
AIDS. 2001 Jan 5;15(1):140-1
11192863
J Virol. 1998 May;72(5):4265-73
9557716